Skip to main content
Journal cover image

Targeted Exome Sequencing of the Cancer Genome in Patients with Very High-risk Bladder Cancer.

Publication ,  Journal Article
Longo, T; McGinley, KF; Freedman, JA; Etienne, W; Wu, Y; Sibley, A; Owzar, K; Gresham, J; Moy, C; Szabo, S; Greshock, J; Zhou, H; Bai, Y; Inman, BA
Published in: Eur Urol
November 2016

UNLABELLED: We completed targeted exome sequencing of the tumors of 50 patients with pTis-pT4b bladder cancer. Mutations were categorized by type, stratified against previously identified cancer loci in the Catalogue of Somatic Mutations in Cancer and The Cancer Genome Atlas databases, and evaluated in pathway analysis and comutation plots. We analyzed mutation associations with receipt of neoadjuvant chemotherapy, nodal involvement, metastatic disease development, and survival. Compared with The Cancer Genome Atlas, we found higher mutation rates in genes encoding products involved in epigenetic regulation and cell cycle regulation. Of the pathways examined, PI3K/mTOR and Cell Cycle/DNA Repair exhibited the greatest frequencies of mutation. RB1 and TP53, as well as NF1 and PIK3CA were frequently comutated. We identified no association between mutations in specific genes and key clinical outcomes of interest when corrected for multiple testing. Discovery phase analysis of the somatic mutations in 50 high-risk bladder cancer patients revealed novel mutations and mutational patterns, which may be useful for developing targeted therapy regimens or new biomarkers for patients at very high risk of disease metastasis and death. PATIENT SUMMARY: In this report we found known, as well as previously unreported, genetic mutations in the tumors of patients with high-risk bladder cancer. These mutations, if validated, may serve as actionable targets for new trials.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Eur Urol

DOI

EISSN

1873-7560

Publication Date

November 2016

Volume

70

Issue

5

Start / End Page

714 / 717

Location

Switzerland

Related Subject Headings

  • Urology & Nephrology
  • Urinary Bladder Neoplasms
  • United States
  • Polymorphism, Single Nucleotide
  • Patient Outcome Assessment
  • Neoplasm Staging
  • Neoplasm Metastasis
  • Neoadjuvant Therapy
  • Mutation Rate
  • Middle Aged
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Longo, T., McGinley, K. F., Freedman, J. A., Etienne, W., Wu, Y., Sibley, A., … Inman, B. A. (2016). Targeted Exome Sequencing of the Cancer Genome in Patients with Very High-risk Bladder Cancer. Eur Urol, 70(5), 714–717. https://doi.org/10.1016/j.eururo.2016.07.049
Longo, Thomas, Kathleen F. McGinley, Jennifer A. Freedman, Wiguins Etienne, Yuan Wu, Alexander Sibley, Kouros Owzar, et al. “Targeted Exome Sequencing of the Cancer Genome in Patients with Very High-risk Bladder Cancer.Eur Urol 70, no. 5 (November 2016): 714–17. https://doi.org/10.1016/j.eururo.2016.07.049.
Longo T, McGinley KF, Freedman JA, Etienne W, Wu Y, Sibley A, et al. Targeted Exome Sequencing of the Cancer Genome in Patients with Very High-risk Bladder Cancer. Eur Urol. 2016 Nov;70(5):714–7.
Longo, Thomas, et al. “Targeted Exome Sequencing of the Cancer Genome in Patients with Very High-risk Bladder Cancer.Eur Urol, vol. 70, no. 5, Nov. 2016, pp. 714–17. Pubmed, doi:10.1016/j.eururo.2016.07.049.
Longo T, McGinley KF, Freedman JA, Etienne W, Wu Y, Sibley A, Owzar K, Gresham J, Moy C, Szabo S, Greshock J, Zhou H, Bai Y, Inman BA. Targeted Exome Sequencing of the Cancer Genome in Patients with Very High-risk Bladder Cancer. Eur Urol. 2016 Nov;70(5):714–717.
Journal cover image

Published In

Eur Urol

DOI

EISSN

1873-7560

Publication Date

November 2016

Volume

70

Issue

5

Start / End Page

714 / 717

Location

Switzerland

Related Subject Headings

  • Urology & Nephrology
  • Urinary Bladder Neoplasms
  • United States
  • Polymorphism, Single Nucleotide
  • Patient Outcome Assessment
  • Neoplasm Staging
  • Neoplasm Metastasis
  • Neoadjuvant Therapy
  • Mutation Rate
  • Middle Aged